2026 · Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · paywalled
Digital signatures of fatigue and wearing-off symptoms in patients with multiple sclerosis under natalizumab
Masanneck et al.
The finding, in our words
Wearing-off symptoms during natalizumab treatment in multiple sclerosis correlate with fatigue but not with inflammatory or neurodegenerative biomarkers, suggesting they are not markers of disease activity. Passive wearable monitoring detected subtle end-of-cycle motor declines and dynamic activity features that aligned with fatigue, indicating potential for digital biomarkers to serve as remote endpoints in decentralised neurological care.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
In progressive multiple sclerosis, higher serum neurofilament light chain levels were associated with reduced daily step counts from wearables, while higher step counts were linked to lower sNfL. A ten percent increase in steps corresponded to a 0.015 decrease in sNfL z-score, suggesting rising sNfL may predict subsequent mobility decline.
Joseph et al., Annals of clinical and translational neurology (paywalled) · source ↗
The High-Definition Oncology feasibility study in 30 women with metastatic cancer demonstrated high adherence to biospecimen collection (97.4% plasma, 80.7% stool) and wearable monitoring (70–95% of days captured for activity, heart rate, sleep, and oxygen saturation). This establishes a viable framework for decentralised, multimodal data collection in oncology to support individualised treatment models.
Garma et al., JCO precision oncology (paywalled) · source ↗
The study demonstrated that longitudinal remote monitoring using wearable sleep electroencephalography, actigraphy, and self-collected saliva samples is feasible in older adults with mild cognitive impairment or dementia, with high retention and data completeness rates over eight weeks.
Merck describes a digitally enabled, patient-centric trial initiative that combines outpatient PK/PD sampling with digital biomarkers and smart dosing technologies to improve exposure-response understanding and reduce patient burden, while acknowledging adoption challenges.
Dockendorf et al., Clinical and translational science · source ↗
Higher plasma BDNF levels were associated with a lower prevalence of sarcopenia and better kinetic and spatiotemporal gait performance in older adults.
Zhang et al., Journal of cachexia, sarcopenia and muscle · source ↗